Skip to main content

Table 2 Definition of classification systems and distribution of the enrolled cases

From: The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer

Classification system Cases Pathological response
NSABP pCR 5 No histological evidence of invasive tumour cells
  pINV 84 Histological evidence of invasive disease of any extent
Miller-Payne G1 10 Some alteration to individual malignant cells but no reduction in overall numbers as compared with the pre-treatment biopsy
  G2 20 A minor loss of invasive tumour cells but overall cellularity still high (<30%)
  G3 40 A moderate reduction of in tumour cells up to an estimated 90% loss (30-90%)
  G4 14 A marked disappearance of invasive tumour cells such that only small clusters of widely dispersed cells could be detected (>90%)
  G5 5 No invasive tumours, i.e., only in situ disease or tumour stroma remained
Sataloff TA 20 Total or near total therapeutic effect
  TB 30 Subjectively greater than 50 % therapeutic effect but less total and near total
  TC 29 Less than 50% therapeutic effect, but effect event
  TD 10 No therapeutic effect
EWGBSP TR1a 4 No residual tumour
  TR1b 1 No residual invasive tumour but presence of residual in situ carcinoma
  TR2a 14 Minimal residual invasive tumour (<10%)
  TR2b 31 Therapeutic effect with residual invasive tumour (10-50%)
  TR2c 29 Therapeutic effect but >50% residual invasive tumour
  TR3 10 No pathologic response
CPS-EG 0 0 Point assignments
  1 2 Clinical stage Pathologic stage Tumour marker
  2 19 I; IIA = 0 0; I = 0 ER negative =1 G34 =1
  3 17 IIB; IIIA = 1 IIA/B; IIIA/B = 1   
  4 12 IIIB; IIIC = 2 IIIC = 2   
  5 5     
  6 0     
  1. 1 NSABP: National Surgical Adjuvant Breast and Bowel Project
  2. 2 EWGBSP: European Working Group for Breast Screening Pathology
  3. 3 CPS-EG: Clinical Pathological Stage combined with Estrogen receptor status and Grade by M.D. Anderson Center (MDACC)
  4. 4G3: grade